Leerink Partners analyst Puneet Souda has maintained their bullish stance on DHR stock, giving a Buy rating on March 28.
Puneet Souda has given his Buy rating due to a combination of factors influencing Danaher’s market position and growth potential. A significant driver is the robust recovery in the market, supported by the strength of the monoclonal antibody (mAb) pipeline and commercial demand. Cytiva, a key component of Danaher, has experienced consistent order growth over six consecutive quarters, indicating strong customer engagement and market presence.
Additionally, Danaher’s strategic focus on technology enhancements through bolt-on acquisitions, particularly in process analytical technology, positions it well for future growth. Despite challenges in China, the long-term importance of this market remains, with trends suggesting increased platforming on established brands like Cytiva. Furthermore, the demand from contract development and manufacturing organizations (CDMOs) and the growing biosimilar market contribute positively to Danaher’s outlook, supporting a favorable equipment demand scenario through 2026.
According to TipRanks, Souda is an analyst with an average return of -13.9% and a 27.22% success rate. Souda covers the Healthcare sector, focusing on stocks such as Illumina, Natera, and Guardant Health.
In another report released on March 28, Guggenheim also maintained a Buy rating on the stock with a $250.00 price target.